Quick Answer
Emmaus Life Sciences, Inc. reported Cash and Equivalents of $2.13 million for fiscal year 2025.
Emmaus Life Sciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $2.13M | +53.1% |
| 2024 | $1.39M | -45.5% |
| 2023 | $2.55M | +26.0% |
| 2022 | $2.02M | -11.3% |
| 2021 | $2.28M | -8.4% |
| 2020 | $2.49M | +40.6% |
| 2019 | $1.77M | +33.4% |
| 2019 | $1.33M | -66.0% |
| 2018 | $3.90M | +20.0% |
| 2018 | $3.25M | -40.3% |
| 2017 | $5.45M | +1612.4% |
| 2016 | $318.2K | -26.4% |
| 2015 | $432.1K | -65.2% |
| 2014 | $1.24M | -2.6% |
| 2013 | $1.27M | +16440.3% |
| 2012 | $7.7K | -89.5% |
| 2011 | $73.6K | +32.9% |
| 2010 | $55.4K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $293.0K | -76.7% | -66.9% |
| June 30, 2025 | $886.0K | -41.9% | -33.5% |
| March 31, 2025 | $1.33M | -22.1% | -4.0% |
| December 31, 2024 | $1.39M | -45.5% | +10.7% |
| September 30, 2024 | $1.25M | -16.6% | -17.7% |
| June 30, 2024 | $1.52M | +12.0% | -10.9% |
| March 31, 2024 | $1.71M | -3.5% | -32.8% |
| December 31, 2023 | $2.55M | +26.0% | +69.2% |
- Emmaus Life Sciences, Inc. showed an increase of +53.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2010–2025 period, Emmaus Life Sciences, Inc.’s cash and equivalents has grown by 3739.4% (from $55.4 thousand to $2.13 million).
- The most recent figure is from Emmaus Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: